Uveitis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Active Biotech AB, Eyevensys, Alumis, Eli Lilly

The Uveitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Uveitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Uveitis Market.

Some of the key takeaways from the Uveitis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Uveitis treatment therapies with a considerable amount of success over the years. 
• Uveitis companies working in the treatment market are Active Biotech AB, Eyevensys, Alumis Inc, Eli Lilly and Company, Tarsier Pharma, and others, are developing therapies for the Uveitis treatment 

• Emerging Uveitis therapies in the different phases of clinical trials are- Laquinimod, EYS606, ESK-001, Baricitinib, TRS01, and others are expected to have a significant impact on the Uveitis market in the coming years.  
• In April 2023, The World Health Organization (WHO) has placed Tarsier Pharma Ltd., a late-stage pharmaceutical business, on the INN Recommended List and awarded its first-in-class immunomodulator TRS an International Nonproprietary Name (INN) of “Dazdotuftide.”
• In September 2021, A Phase III randomized, active-controlled, double-masked trial was started by Tarsier Pharma to assess the safety and effectiveness of TRS01 eye drops in treating patients with active non-infectious anterior uveitis, including those with uveitic glaucoma.
• In October 2021, The United States Food and Drug Administration (FDA) has approved XIPERE (triamcinolone acetonide), according to a statement from Bausch + Lomb and Clearside Biomedical. An injectable suspension called XIPERE is given via the suprachoroidal method to treat macular edema brought on by uveitis.
• In December 2020, In the Netherlands, Alimera Sciences Europe Limited has introduced ILUVIEN. ILUVIEN is used to treat posterior segment non-infectious uveitis and diabetic macular edema (DME) (NIPU). Geographic expansion is the launch strategy, which aims to make ILUVIEN accessible to more doctors and patients in new markets.

Uveitis Overview

The illness condition known as uveitis causes inflammation in the eyes. A wide range of disease types together known as uveitis have been estimated to cause 10% of blindness. Acute, intermediate, posterior, and panuveitis are the four main categories of uveitis according to the eye’s anatomical involvement.

Get a Free Sample PDF Report to know more about Uveitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/uveitis-pipeline-insight

Emerging Uveitis Drugs Under Different Phases of Clinical Development Include:

• Laquinimod: Active Biotech AB
• EYS606: Eyevensys
• ESK-001: Alumis Inc
• Baricitinib: Eli Lilly and Company
• TRS01: Tarsier Pharma

Uveitis Route of Administration

Uveitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Uveitis Molecule Type

Uveitis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Uveitis Pipeline Therapeutics Assessment

• Uveitis Assessment by Product Type
• Uveitis By Stage and Product Type
• Uveitis Assessment by Route of Administration
• Uveitis By Stage and Route of Administration
• Uveitis Assessment by Molecule Type
• Uveitis by Stage and Molecule Type

DelveInsight’s Uveitis Report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Uveitis product details are provided in the report. Download the Uveitis pipeline report to learn more about the emerging Uveitis therapies

Some of the key companies in the Uveitis Therapeutics Market include:

Key companies developing therapies for Uveitis are – AbbVie (Allergan), Inc., Novartis AG, Bausch Health Inc., AbbVie Inc., Eyegate Pharmaceuticals, Inc., Alimera Science Inc., EyePoint Pharmaceuticals, Santen Pharmaceuticals, and others.

Uveitis Pipeline Analysis:

The Uveitis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Uveitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uveitis Treatment.
• Uveitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Uveitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Uveitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Uveitis drugs and therapies

Uveitis Pipeline Market Drivers

• Increasing Prevalence of Uveitis, increase in Research and developmental Activities are some of the important factors that are fueling the Uveitis Market.

Uveitis Pipeline Market Barriers

• However, high cost associated with the treatment, lack of skilled professionals and other factors are creating obstacles in the Uveitis Market growth.

Scope of Uveitis Pipeline Drug Insight    

• Coverage: Global
• Key Uveitis Companies: Active Biotech AB, Eyevensys, Alumis Inc, Eli Lilly and Company, Tarsier Pharma, and others
• Key Uveitis Therapies: Laquinimod, EYS606, ESK-001, Baricitinib, TRS01, and others
• Uveitis Therapeutic Assessment: Uveitis current marketed and Uveitis emerging therapies
• Uveitis Market Dynamics: Uveitis market drivers and Uveitis market barriers 

Request for Sample PDF Report for Uveitis Pipeline Assessment and clinical trials

Table of Contents

1. Uveitis Report Introduction

2. Uveitis Executive Summary

3. Uveitis Overview

4. Uveitis- Analytical Perspective In-depth Commercial Assessment

5. Uveitis Pipeline Therapeutics

6. Uveitis Late Stage Products (Phase II/III)

7. Uveitis Mid Stage Products (Phase II)

8. Uveitis Early Stage Products (Phase I)

9. Uveitis Preclinical Stage Products

10. Uveitis Therapeutics Assessment

11. Uveitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Uveitis Key Companies

14. Uveitis Key Products

15. Uveitis Unmet Needs

16 . Uveitis Market Drivers and Barriers

17. Uveitis Future Perspectives and Conclusion

18. Uveitis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services